Blueprint Medicines' Ayvakit (avapritinib) Receives FDA's Approval to Treat Patients with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor
Shots:
- The US FDA approval is based on P-I NAVIGATOR trial assessing avapritinib (300mg or 400mg- qd) in 43 patients with unresectable or metastatic GIST harboring PDGFRA exon 18 mutations- including 38 patients with PDGFRA D842V mutations
- The study resulted in patients with PDGFRA exon 18 mutant GIST: ORR 84%- CR 7%- PR 77%. And in patients with PDGFRA D842V mutations: ORR 89%- CR 8%- PR 82%- mDOR was not reached
- Ayvakit (avapritinib) is a KIT and PDGFRA mutant kinases inhibitor and is novel candidate approved for type 1 inhibitor for GIST and has also received the US FDA’s BT Designation. The PDUFA date for fourth-line GIST indication is currently Feb 14- 2020
Click here to read full press release/ article | Ref: Blueprint Medicines | Image: Twitter
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com